PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell(Mayo Clinic in Arizona), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Ivan Borrello(Johns Hopkins University), Ahmad Halwani(University of Utah), Emma C. Scott(Oregon Health & Science University), Martin Gutierrez(Hackensack University Medical Center), Stephen J. Schuster(UPMC Hillman Cancer Center), Michael Millenson(Fox Chase Cancer Center), Deepika Cattry(Memorial Sloan Kettering Cancer Center), Gordon J. Freeman(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Bjoern Chapuy(Harvard University), Azra H. Ligon(Brigham and Women's Hospital), Lili Zhu(Bristol-Myers Squibb (Belgium)), Joseph F. Grosso(Bristol-Myers Squibb (Belgium)), Su Young Kim(Bristol-Myers Squibb (Belgium)), John M. Timmerman(University of California, Los Angeles), Margaret A. Shipp(Harvard University), Philippe Armand(Harvard University)
Cited by 3,538Open Access
Abstract
Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
Related Papers
No related papers found
Powered by citation graph analysis